Company intelligence / Profile preview

AdipoGenix

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

AdipoGenix was a biotechnology company focused on the discovery and development of novel therapeutics for obesity and related metabolic disorders. The company utilized a proprietary platform based on human adipocyte (fat cell) biology to identify targets and small molecule leads that could modulate fat storage and metabolism. Founded in 1998 and headquartered in Boston, AdipoGenix leveraged its expertise in adipose tissue to build an early-stage pipeline of metabolic drug candidates. In September 2000, the company was acquired by Genzyme Corporation for approximately $8 million to bolster Genzyme's internal research and development efforts in the metabolic disease area.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AdipoGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdipoGenix.

Explore the full profile